Hardman Research: IONA sales & litigation update

Hardman & Co research: IONA sales & litigation update

Premaitha uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests. IONA® uses complex statistical analysis to determine the likelihood that a fetus is carrying a disorder such as Down's syndrome or other prenatal genetic abnormalities. Although IONA has entered a competitive and litigious market, it has some advantages, is CE Marked, and was first to win UK NHS contracts. Early signs of commercial traction for IONA were evident in the trading update. Also, a recent court hearing has positive outcomes: amalgamating all the defences against patent infringement brought by Illumina, delaying the potential start of the trial, and joining Premaitha up with Roche.

Please click here for the full report:

http://www.hardmanandco.com/docs/default-source/company-docs/premaitha-health-plc-documents/20-04-16-solid-first-year-iona-sales-positive-litigation-update

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.